Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Structural analyses of inositol phosphate second messengers bound to signaling effector proteins.

Blind RD.

Adv Biol Regul. 2019 Oct 11:100667. doi: 10.1016/j.jbior.2019.100667. [Epub ahead of print] Review.

PMID:
31648945
2.

Human islets expressing HNF1A variant have defective β cell transcriptional regulatory networks.

Haliyur R, Tong X, Sanyoura M, Shrestha S, Lindner J, Saunders DC, Aramandla R, Poffenberger G, Redick SD, Bottino R, Prasad N, Levy SE, Blind RD, Harlan DM, Philipson LH, Stein RW, Brissova M, Powers AC.

J Clin Invest. 2019 Jan 2;129(1):246-251. doi: 10.1172/JCI121994. Epub 2018 Dec 3.

3.

Crystallographic and kinetic analyses of human IPMK reveal disordered domains modulate ATP binding and kinase activity.

Seacrist CD, Blind RD.

Sci Rep. 2018 Nov 12;8(1):16672. doi: 10.1038/s41598-018-34941-3.

4.

Signaling through non-membrane nuclear phosphoinositide binding proteins in human health and disease.

Bryant JM, Blind RD.

J Lipid Res. 2019 Feb;60(2):299-311. doi: 10.1194/jlr.R088518. Epub 2018 Sep 10.

PMID:
30201631
5.

Nuclear phosphoinositide regulation of chromatin.

Hamann BL, Blind RD.

J Cell Physiol. 2018 Jan;233(1):107-123. doi: 10.1002/jcp.25886. Epub 2017 May 3. Review.

PMID:
28256711
6.

Phospholipid regulation of the nuclear receptor superfamily.

Crowder MK, Seacrist CD, Blind RD.

Adv Biol Regul. 2017 Jan;63:6-14. doi: 10.1016/j.jbior.2016.10.006. Epub 2016 Oct 29. Review.

7.

Inositol polyphosphate multikinase (IPMK) in transcriptional regulation and nuclear inositide metabolism.

Malabanan MM, Blind RD.

Biochem Soc Trans. 2016 Feb;44(1):279-85. doi: 10.1042/BST20150225. Review.

8.

Structure of Liver Receptor Homolog-1 (NR5A2) with PIP3 hormone bound in the ligand binding pocket.

Sablin EP, Blind RD, Uthayaruban R, Chiu HJ, Deacon AM, Das D, Ingraham HA, Fletterick RJ.

J Struct Biol. 2015 Dec;192(3):342-348. doi: 10.1016/j.jsb.2015.09.012. Epub 2015 Sep 28.

9.

The signaling phospholipid PIP3 creates a new interaction surface on the nuclear receptor SF-1.

Blind RD, Sablin EP, Kuchenbecker KM, Chiu HJ, Deacon AM, Das D, Fletterick RJ, Ingraham HA.

Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15054-9. doi: 10.1073/pnas.1416740111. Epub 2014 Oct 6.

10.

Disentangling biological signaling networks by dynamic coupling of signaling lipids to modifying enzymes.

Blind RD.

Adv Biol Regul. 2014 Jan;54:25-38. doi: 10.1016/j.jbior.2013.09.015. Epub 2013 Oct 18. Review.

11.

Direct modification and activation of a nuclear receptor-PIP₂ complex by the inositol lipid kinase IPMK.

Blind RD, Suzawa M, Ingraham HA.

Sci Signal. 2012 Jun 19;5(229):ra44. doi: 10.1126/scisignal.2003111.

12.

Ligand structural motifs can decouple glucocorticoid receptor transcriptional activation from target promoter occupancy.

Blind RD, Pineda-Torra I, Xu Y, Xu HE, Garabedian MJ.

Biochem Biophys Res Commun. 2012 Apr 20;420(4):839-44. doi: 10.1016/j.bbrc.2012.03.084. Epub 2012 Mar 23.

13.

Small molecule agonists of the orphan nuclear receptors steroidogenic factor-1 (SF-1, NR5A1) and liver receptor homologue-1 (LRH-1, NR5A2).

Whitby RJ, Stec J, Blind RD, Dixon S, Leesnitzer LM, Orband-Miller LA, Williams SP, Willson TM, Xu R, Zuercher WJ, Cai F, Ingraham HA.

J Med Chem. 2011 Apr 14;54(7):2266-81. doi: 10.1021/jm1014296. Epub 2011 Mar 10.

14.

Regulation of C. elegans fat uptake and storage by acyl-CoA synthase-3 is dependent on NR5A family nuclear hormone receptor nhr-25.

Mullaney BC, Blind RD, Lemieux GA, Perez CL, Elle IC, Faergeman NJ, Van Gilst MR, Ingraham HA, Ashrafi K.

Cell Metab. 2010 Oct 6;12(4):398-410. doi: 10.1016/j.cmet.2010.08.013.

15.

Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.

Lin BC, Suzawa M, Blind RD, Tobias SC, Bulun SE, Scanlan TS, Ingraham HA.

Cancer Res. 2009 Jul 1;69(13):5415-23. doi: 10.1158/0008-5472.CAN-08-1622. Epub 2009 Jun 23.

16.

Structure of SF-1 bound by different phospholipids: evidence for regulatory ligands.

Sablin EP, Blind RD, Krylova IN, Ingraham JG, Cai F, Williams JD, Fletterick RJ, Ingraham HA.

Mol Endocrinol. 2009 Jan;23(1):25-34. doi: 10.1210/me.2007-0508. Epub 2008 Nov 6.

17.

Applying innovative educational principles when classes grow and resources are limited: Biochemistry experiences at Muhimbili University of Allied Health Sciences.

Omer S, Hickson G, Taché S, Blind R, Masters S, Loeser H, Souza K, Mkony C, Debas H, O'Sullivan P.

Biochem Mol Biol Educ. 2008 Nov;36(6):387-94. doi: 10.1002/bmb.20210.

18.

Glucocorticoid receptor phosphorylation differentially affects target gene expression.

Chen W, Dang T, Blind RD, Wang Z, Cavasotto CN, Hittelman AB, Rogatsky I, Logan SK, Garabedian MJ.

Mol Endocrinol. 2008 Aug;22(8):1754-66. doi: 10.1210/me.2007-0219. Epub 2008 May 15.

19.

Differential recruitment of glucocorticoid receptor phospho-isoforms to glucocorticoid-induced genes.

Blind RD, Garabedian MJ.

J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):150-7. doi: 10.1016/j.jsbmb.2008.01.002. Epub 2008 Jan 19.

20.

Stabilization of the unliganded glucocorticoid receptor by TSG101.

Ismaili N, Blind R, Garabedian MJ.

J Biol Chem. 2005 Mar 25;280(12):11120-6. Epub 2005 Jan 18.

Supplemental Content

Loading ...
Support Center